Andere talen Acumen Pharmaceuticals, Inc.

Aandelen

ABOS

US00509G2093

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 22-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,6 ^USD	-5,51%		-5,26%	-6,25%

15/05	Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM
14/05	Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights	14/05
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference	08/05
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study	08/05
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease	08/05
Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease	08/05
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024	07/05
AAN 2024 Poster - INTERCEPT-AD, a Phase 1 Study of Sabirnetug (ACU193): Safety, Target Engagement, and Biomarker Changes	02/05
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting	17/04
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting	16/04
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04/04
Borsa svizzera chiude in rialzo, SMI +0,64%	04/04
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04/04
Lonza produziert Arzneimittelkandidaten von Acumen Pharmaceuticals	04/04
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease	04/04
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04/04
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	27/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights	26/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Acumen Pharmaceuticals, Inc.

Aandelen

ABOS

US00509G2093

Andere talen

Filters